Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C19 | P33261 | 1/20 | 0.52 |
| ▸ | PSEN1 | P49768 | 1/20 | 0.41 |
| ▸ | PSEN2 | P49810 | 1/20 | 0.41 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.41 |
| ▸ | APH1B | Q8WW43 | 1/20 | 0.41 |
| ▸ | NCSTN | Q92542 | 1/20 | 0.41 |
| ▸ | APH1A | Q96BI3 | 1/20 | 0.41 |
| ▸ | PSENEN | Q9NZ42 | 1/20 | 0.41 |
| ▸ | APP | P05067 | 1/20 | 0.41 |
| ▸ | DPP4 | P27487 | 7/20 | 0.39 |
| ▸ | DPP8 | Q6V1X1 | 2/20 | 0.39 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.39 |
| ▸ | CYP17A1 | P05093 | 1/20 | 0.37 |
| ▸ | DCK | P27707 | 4/20 | 0.36 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.35 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.35 |
| ▸ | ACACB | O00763 | 1/20 | 0.34 |
| ▸ | ELOVL1 | Q9BW60 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18952491 | 1.00 | CYP2C19 (0.52) | CYP2C19PSEN1PSEN2KCNH2APH1B | |
| SCHEMBL21374619 | 1.00 | CYP2C19 (0.52) | CYP2C19PSEN1PSEN2KCNH2APH1B | |
| SCHEMBL18952489 | 1.00 | CYP2C19 (0.52) | CYP2C19PSEN1PSEN2KCNH2APH1B | |
| SCHEMBL18971147 | 1.00 | CYP2C19 (0.52) | CYP2C19PSEN1PSEN2KCNH2APH1B | |
| SCHEMBL22638877 | 0.82 | CYP2C19 (0.55) | CYP2C19PSEN1PSEN2KCNH2APH1B | |
| SCHEMBL20159989 | 0.81 | CYP2C19 (0.51) | CYP2C19PSEN1PSEN2KCNH2APH1B | |
| SCHEMBL20609174 | 0.80 | PSEN1 (0.42) | PSEN1PSEN2KCNH2APH1BNCSTN | |
| SCHEMBL18971430 | 0.80 | PSEN1 (0.42) | PSEN1PSEN2KCNH2APH1BNCSTN | |
| SCHEMBL18970933 | 0.80 | PSEN1 (0.42) | PSEN1PSEN2KCNH2APH1BNCSTN | |
| SCHEMBL20609175 | 0.80 | PSEN1 (0.42) | PSEN1PSEN2KCNH2APH1BNCSTN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11319314-B2 | Phenoxytriazoles | HOFFMANN-LA ROCHE INC. (US) | 2022-05-03 | — | — | US | disclosed |
| EP-3535266-B1 | BICYCLIC HETEROARYL DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2021-12-29 | — | — | EP | disclosed |
| EP-3519418-B1 | BRIDGED PIPERIDINE DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2021-12-08 | — | — | EP | disclosed |
| US-20210309653-A1 | PHENOXYTRIAZOLES | HOFFMANN-LA ROCHE INC. (US) | 2021-10-07 | — | — | US | disclosed |
| EP-3538516-B1 | PHENOXYTRIAZOLES | HOFFMANN LA ROCHE (CH) | 2021-06-16 | — | — | EP | disclosed |
| US-10941147-B2 | Bicyclic heteroaryl derivatives | HOFFMANN-LA ROCHE INC. (US) | 2021-03-09 | — | — | US | disclosed |
| EP-3386978-B1 | BRIDGED PIPERIDINE DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2021-01-27 | — | — | EP | disclosed |
| EP-3484884-B1 | FUSED PYRIMIDINE DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2021-01-27 | — | — | EP | disclosed |
| US-10899766-B2 | Bridged piperidine derivatives | HOFFMANN-LA ROCHE INC. (US) | 2021-01-26 | — | — | US | disclosed |
| US-20200291034-A1 | BRIDGED PIPERIDINE DERIVATIVES | HOFFMANN-LA ROCHE INC. (US) | 2020-09-17 | — | — | US | disclosed |
| US-10730881-B2 | Fused pyrimidine derivatives | HOFFMANN-LA ROCHE, INC. (US) | 2020-08-04 | — | — | US | disclosed |
| US-20200031831-A1 | BRIDGED PIPERIDINE DERIVATIVES | HOFFMANN-LA ROCHE INC. (US) | 2020-01-30 | — | — | US | disclosed |
| US-20190284191-A1 | BICYCLIC HETEROARYL DERIVATIVES | HOFFMANN-LA ROCHE INC. (US) | 2019-09-19 | — | — | US | disclosed |
| US-20190177329-A1 | FUSED PYRIMIDINE DERIVATIVES | HOFFMANN-LA ROCHE INC. (US) | 2019-06-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210309653-A1 | PHENOXYTRIAZOLES | HTT, PSEN1, APP | CYP2C19 3576/4885PSEN1 2/4885PSEN2 7/4885 |
| US-10730881-B2 | Fused pyrimidine derivatives | APP, UPF1, PSEN1 | CYP2C19 3050/4885PSEN1 3/4885PSEN2 10/4885 |
| US-20200031831-A1 | BRIDGED PIPERIDINE DERIVATIVES | PSEN1, APP, PRNP | CYP2C19 3584/4885PSEN1 1/4885PSEN2 5/4885 |
| US-20190284191-A1 | BICYCLIC HETEROARYL DERIVATIVES | HUWE1, APP, HTT | CYP2C19 3283/4885PSEN1 18/4885PSEN2 40/4885 |
| US-10941147-B2 | Bicyclic heteroaryl derivatives | HUWE1, APP, HTT | CYP2C19 3283/4885PSEN1 18/4885PSEN2 40/4885 |
| US-10899766-B2 | Bridged piperidine derivatives | PSEN1, APP, PRNP | CYP2C19 3584/4885PSEN1 1/4885PSEN2 5/4885 |
| US-20200291034-A1 | BRIDGED PIPERIDINE DERIVATIVES | PTGDR, HPGDS, PSEN1 | CYP2C19 2996/4885PSEN1 3/4885PSEN2 21/4885 |
| US-20190177329-A1 | FUSED PYRIMIDINE DERIVATIVES | APP, UPF1, PSEN1 | CYP2C19 3050/4885PSEN1 3/4885PSEN2 10/4885 |
| US-11319314-B2 | Phenoxytriazoles | HTT, APP, PSEN1 | CYP2C19 3156/4885PSEN1 3/4885PSEN2 11/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.